West Pharmaceutical (WST) Q2 2025: HVP Components Up 11%, Biologics and Annex 1 Drive Multi-Year Tailwind
West Pharmaceutical’s Q2 outperformance was fueled by a sharp rebound in high-value product (HVP) components, with biologics and regulatory-driven upgrades setting the stage for sustained growth. Margin expansion and disciplined capital allocation reinforce the company’s long-term construct, while operational levers and network optimization support resilience against tariff and supply chain risk.
Summary
- HVP Momentum Accelerates: High-value product components, led by GLP-1 and biologics, are restoring growth and margin trajectory.
- Annex 1 Pipeline Builds: Regulatory-driven HVP upgrades are translating into a growing, multi-year commercial opportunity.
- Operational Leverage Expands: Asset utilization and network optimization are supporting margin gains and future capacity flexibility.
Performance Analysis
West’s Q2 2025 results mark a decisive return to growth, with net sales growing on both a reported and organic basis, propelled by HVP components. The proprietary products segment, accounting for the bulk of the business, saw strong organic expansion, with HVP components up 11.3% and now representing 74% of proprietary product sales. Biologics and generics both delivered high single-digit growth, with Annex 1 regulatory projects and GLP-1 elastomer demand serving as major drivers. These factors, combined with pricing power and positive volume/mix, fueled a 290 basis point year-over-year gross margin improvement and a 21% jump in adjusted EPS.
Contract manufacturing, which is roughly 13% of total sales, contributed modest growth as the Dublin facility ramps up for auto-injectors and pens, partially offsetting headwinds in legacy CGM diagnostics. Cash flow and balance sheet strength provided further stability, with operating cash flow up 8% and capital expenditures trending down as major investments normalize. Margin expansion was underpinned by higher plant efficiency and favorable business mix, reflecting both demand normalization and disciplined cost control.
- HVP Component Demand Surges: GLP-1 elastomer products reached 8% of total sales, with biologics and Annex 1 upgrades driving incremental wins.
- Margin Expansion Outpaces Revenue: Gross margin rose 290 basis points year-over-year, powered by product mix and plant efficiency.
- Contract Manufacturing Ramps: Auto-injector and pen production in Dublin is offsetting CGM device lifecycle headwinds, positioning the segment for future growth.
The quarter’s results confirm that HVP-led growth and regulatory tailwinds are restoring West’s historical growth construct, with the second half of 2025 expected to accelerate further as new capacity and customer projects come online.
Executive Commentary
"This strong performance was the result of robust GLP-1 elastomer growth, ongoing momentum in HVP conversions impacted by Annex 1 activity, and the continued normalization of customer ordering patterns. Our improved performance was concentrated in our higher margin businesses, which drove a favorable margin expansion in the quarter."
Eric Green, Chairman and CEO
"High-value products, which made up 74% of proprietary product sales in the quarter, increased 12.6%, led by customer demand for Westar and Nova Choice products. Our gross profit margin of 35.7% was a 290 basis point year-over-year increase."
Bernard, CFO
Strategic Positioning
1. HVP Component Leadership and Biologics Penetration
HVP components, defined as West’s highest-margin elastomer and containment solutions, are reasserting their role as the primary growth and profit engine. The GLP-1 drug class, along with biologics and biosimilars, is driving both volume and pricing gains. West’s participation rate in these categories is trending above historical levels, and the company is leveraging pandemic-era investments to meet surging demand without incremental capital intensity.
2. Annex 1 Regulatory Upgrades Create Multi-Year Pipeline
Annex 1, a set of EU regulations mandating higher standards for sterile drug manufacturing, is catalyzing a significant multi-year upgrade cycle. West’s backlog of 370 projects (up from 340 last quarter) provides visibility into future HVP conversions, with management estimating a 150 basis point revenue contribution in 2025. The project pipeline is staggered, with commercialization timelines ranging from two to four quarters, supporting durable growth beyond 2025.
3. Network Optimization and Tariff Mitigation
West’s global manufacturing network, anchored by five centers of excellence, is being optimized through technology transfers and regional alignment. This strategy not only improves service levels but also mitigates tariff exposure by enabling in-region production for local markets. Management is proactively validating products across multiple sites to ensure supply continuity and cost resilience.
4. SmartDOS Automation and Device Expansion
SmartDOS, West’s advanced drug delivery device, is undergoing automation, with a new line set for early 2026. This initiative aims to enhance device economics and margin profile, with initial data supporting meaningful cost improvements. The device business, including dikeo-crystalline containment systems, posted 30% revenue growth in Q2, signaling traction in delivery solutions.
5. Contract Manufacturing Transition and Capacity Leverage
Contract manufacturing is in transition, as auto-injector and pen volumes ramp in Dublin to offset the wind-down of a legacy CGM device. The facility is expected to reach optimized capacity over nine to twelve months, with new customer opportunities in the pipeline for 2026 and beyond. This segment provides optionality for growth and operational leverage as device mix shifts toward higher-margin platforms.
Key Considerations
Q2’s results reflect a turning point for West, as HVP-led growth, regulatory-driven upgrades, and operational discipline converge to restore the company’s long-term growth construct. Investors should weigh the following:
Key Considerations:
- HVP Growth Outpaces Legacy: High-value components are eclipsing standard products, reshaping both revenue mix and profitability.
- Annex 1 Pipeline Visibility: The growing project backlog provides multi-year revenue visibility, though commercialization pacing varies by customer.
- Tariff and FX Dynamics: Management is actively mitigating tariff risk through network alignment and has benefited from a positive FX swing in 2025 guidance.
- Device and Contract Manufacturing Shift: The ramp in auto-injectors and SmartDOS automation are critical to offsetting legacy device headwinds and sustaining segment growth.
- Capital Discipline Restored: CapEx is normalizing to 6-8% of revenue, reflecting a maturing investment cycle and improved free cash flow outlook.
Risks
Tariff volatility remains a material risk, with management estimating a $15-$20 million headwind for 2025 but noting ongoing uncertainty and potential for retaliatory actions. Biologics and device ramp timing could introduce variability in near-term revenue, while labor constraints in key European facilities present execution risk if hiring and training lags demand. Regulatory or customer-driven delays in Annex 1 project commercialization could impact the multi-year growth trajectory.
Forward Outlook
For Q3 2025, West guided to:
- Revenue of $785 to $795 million (2.5-3.5% organic growth)
- Adjusted diluted EPS of $1.65 to $1.70
For full-year 2025, management raised guidance:
- Net sales of $3.04 billion to $3.06 billion (organic growth 3-3.75%)
- Adjusted diluted EPS of $6.65 to $6.85
Management highlighted several factors that shape the outlook:
- HVP components expected to grow mid to high single digits for the year, with stronger second-half momentum
- Annex 1 upgrades and biologics demand to drive incremental growth into 2026
Takeaways
West’s Q2 results validate the return of its high-value growth algorithm, with regulatory-driven upgrades and biologics penetration setting up a multi-year tailwind. Margin expansion and capital discipline reinforce the long-term construct, while operational levers and network optimization provide resilience against external shocks.
- HVP-Led Growth Restored: The pivot back to high-value products is driving both top-line and margin expansion, with biologics and Annex 1 upgrades underpinning visibility.
- Operational Flexibility: Network optimization and automation initiatives are enhancing supply resilience and cost management, supporting future device and contract manufacturing growth.
- Watch Pipeline Conversion: Investors should monitor the pacing of Annex 1 project commercialization and the ramp of new device platforms as key levers for sustained growth through 2026.
Conclusion
West Pharmaceutical is reestablishing its high-value product engine, with regulatory and biologics tailwinds translating into improved growth and profitability. The company’s operational and capital discipline, combined with a robust multi-year project pipeline, position it well for durable outperformance, though tariff and execution risks warrant continued vigilance.
Industry Read-Through
West’s results signal a broader inflection for injectable drug delivery and packaging suppliers, as regulatory-driven upgrades and biologics demand reshape the competitive landscape. The Annex 1 upgrade cycle is likely to benefit incumbents with scale and quality advantages, while network optimization and in-region manufacturing are emerging as critical levers to manage tariff risk and supply chain volatility. Device players with automation and flexible capacity are best positioned to capture the next wave of growth as pharma customers prioritize resilience and regulatory compliance.